Cell Saver Systems
Closed State & local contract opportunity Posted
- Solicitation number
- 2137630
- State
- New York
- Responses due
Opportunity facts
- Jurisdiction
- Point of contact
-
- Omar Santiago omar.santiago@stonybrookmedicine.edu (631) 444-4053
Updated .
About this opportunity
Stony Brook University Hospital is requesting quotes for six Xtra Cell Saver Systems manufactured by LivaNova, with proposals due August 25, 2026. This is a single-source procurement where the hospital specifies replacement with the same manufacturer and platform to maintain departmental standardization and operational efficiency.
The Xtra Cell Saver System collects, processes, and returns the patient's own blood during cardiac and major surgical procedures anticipated to involve significant blood loss. The system supports autologous transfusion, reducing reliance on allogeneic blood products, preserving hemoglobin levels, and decreasing transfusion-related risks.
Vendors proposing equivalent systems must demonstrate clinical and operational equivalency through documentation. No SDVOB goal or other set-aside applies to this procurement. Vendors must comply with NYS Finance Law 139 j&k (Lobbying Law) and may contact only the procurement officer listed in the notice before the due date. The successful contractor must complete vendor-responsibility certifications under NYS Finance Law 139, submit valid NYS Tax Law Section 5-a documentation, and provide current NYS Workers' Compensation and Disability insurance forms. No incumbent information is provided. The source does not specify contract value or term.
Opportunity text
Stony Brook University Hospital is proposing to purchase six (6) Xtra Cell Saver Systems manufactured by LivaNova. The Xtra Cell Saver System is an essential component of cardiac and other major surgical procedures where significant blood loss is anticipated. The system collects, processes, and returns the patient's own blood (autologous transfusion), reducing reliance on allogeneic blood products while helping preserve hemoglobin levels, decrease transfusion-related risks, and improve overall patient outcomes. The system consistently produces high hematocrit autologous blood, contributing to reduced utilization of banked blood products and supporting the hospital's patient blood management initiatives. Replacement with the same manufacturer and platform is recommended to maintain departmental standardization and operational efficiency.Any vendor who believes they can provide this product is invited to contact the officer below for a copy of the specifications or to discuss this opportunity before the due date stated in the advertisement. Equivalency must be demonstrated by providing clinical and operational documentation of the proposed system or device. This procurement is subject to NYS Finance Law §139 j&k, AKA the Lobbying Law. Therefore, vendors are cautioned that the only permissible contact for this procurement is the individual listed below. Failure to comply with this requirement can range from no contract to debarment from sales to any NYS Agency. The successful contractor shall be required to complete and submit documents relating to Vendor Responsibility, NYS Finance Law 139, NYS Tax Law Section 5-a, andvalid/current NYS Workman's Compensation and Disability Forms. If you propose to submit a quote, it must be received by COB of the due date. Business enterprises awarded an identical or substantially similar procurement contract within the past five years: None Service-Disabled Veteran-Owned Business (SDVOB) SDVOB Goal: 0.00% Minority / Women Business Enterprise contracting goals (MWBE) Total MWBE Goals: 0.00% Disadvantaged Business Enterprise contracting goals (DBE) DBE Goal: 0.00%
On GovTribe
Work this opportunity
- Track it in your pipeline
- Similar opportunities
- Ask GovTribe AI about this opportunity